arrow_back Back to App

Increased Unannounced Inspections of Foreign Drug Facilities for Safety

This new bill establishes a pilot program to increase unannounced inspections of foreign drug manufacturing facilities. The goal is to ensure imported medicines meet the same safety and quality standards as domestically produced drugs. This provides citizens with greater confidence in the safety and quality of available medications.
Key points
More unannounced inspections of foreign drug factories to identify more violations.
Evaluation of differences between domestic and foreign inspections, including the impact of advance notice.
A public report on the pilot program will be made available, increasing transparency and accountability.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_6980
Sponsor: Rep. Hudson, Richard [R-NC-8]
Process start date: 2022-03-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To direct the Secretary of Health and Human Services to conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6980.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-08.

What are the main provisions?

Key points include:

  • More unannounced inspections of foreign drug factories to identify more violations.
  • Evaluation of differences between domestic and foreign inspections, including the impact of advance notice.
  • A public report on the pilot program will be made available, increasing transparency and accountability.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Hudson, Richard [R-NC-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health